STSergey V. Tokalov

Sergey V. Tokalov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergey V. Tokalov has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Herwig O. Gutzeit

    Institut für Zoologie, TU Dresden, D‐01062 Dresden, Germany

    5 shared publications
  • Nasreddin Abolmaali

    OncoRay – Center for Radiation Research in Oncology, Biological and Molecular Imaging, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Germany

    5 shared publications
  • Andrij Abramyuk

    OncoRay – Center for Radiation Research in Oncology, Biological and Molecular Imaging, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Germany

    4 shared publications
  • Gunter Wolf

    OncoRay – Center for Radiation Research in Oncology, Biological and Molecular Imaging, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Germany

    3 shared publications
  • Klaus Zöphel

    OncoRay – Center for Radiation Research in Oncology, Biological and Molecular Imaging, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Germany

    3 shared publications
  • Michael Baumann

    European Academy of Cancer Sciences Stockholm Sweden

    3 shared publications

Latest Publications

  • Open Access

    Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis—an animal experimental prospective cohort study

    by Martin Mirus, Sergey V. Tokalov, Andrij Abramyuk, Jessica Heinold, Vincent Prochnow, Klaus Zöphel, Jörg Kotzerke, Nasreddin Abolmaali

    This study investigated the noninvasive assessment of tumor vascularization with clinical F-18-fluorodeoxyglucose positron emission tomography/computed tomography and contrast-enhanced computed tomography ([18F]FDG-PET/CT and CE-CT) in experimental human xenograft tumors with modifiable vascularization and compared results to histology. Tumor xenografts with modifiable vascularization were established in 71 athymic nude rats by subcutaneous transplantation of human non-small-cell lung cancer (NSCLC) cells. Four different groups were transplanted with two different tumor cell lines (either A549 or H1299) alone or tumors co-transplanted with rat glomerular endothelial (RGE) cells, the latter to increase vascularization. Tumors were assessed noninvasively by [18F]FDG PET/CT and contrast-enhanced CT (CE-CT) using clinical scanners. This was followed by histological examinations evaluating tumor vasculature (CD-31 and intravascular fluorescent beads). In both tumor lines (A549 and H1299), co-transplantation of RGE cells resulted in faster growth rates [maximal tumor diameter of 20 mm after 22 (± 1.2) as compared to 45 (± 1.8) days, p < 0.001], higher microvessel density (MVD) determined histologically after CD-31 staining [171.4 (± 18.9) as compared to 110.8 (± 11) vessels per mm2, p = 0.002], and higher perfusion as indicated by the number of beads [1.3 (± 0.1) as compared to 1.1 (± 0.04) beads per field of view, p = 0.001]. In [18F]FDG-PET/CT, co-transplanted tumors revealed significantly higher standardized uptake values [SUVmax, 2.8 (± 0.2) as compared to 1.1 (± 0.1), p < 0.001] and larger metabolic active volumes [2.4 (± 0.2) as compared to 0.4 (± 0.2) cm3, p < 0.001] than non-co-transplanted tumors. There were significant correlations for vascularization parameters derived from histology and [18F]FDG PET/CT [beads and SUVmax, r = 0.353, p = 0.005; CD-31 and SUVmax, r = 0.294, p = 0.036] as well as between CE-CT and [18F]FDG PET/CT [contrast enhancement and SUVmax, r = 0.63, p < 0.001; vital CT tumor volume and metabolic PET tumor volume, r = 0.919, p < 0.001]. In this study, a human xenograft tumor model with modifiable vascularization implementable for imaging, pharmacological, and radiation therapy studies was successfully established. Both [18F]FDG-PET/CT and CE-CT are capable to detect parameters closely connected to the degree of tumor vascularization, thus they can help to evaluate vascularization in tumors noninvasively. [18F]FDG-PET may be considered for characterization of tumors beyond pure glucose metabolism and have much greater contribution to diagnostics in oncology.


    • 1 April 2012
      • Vol. 32  (4) , 1239-43

    Radiosensitization of p53-deficient lung cancer cells by pre-treatment with cytostatic compounds.

    by Sergey Tokalov, Nasreddin Abolmaali

    This study specifies a strategy to improve radiotherapy by partial synchronization of p53-deficient cancer cells (FaDu and H1299) in mitosis using taxol, with protecting p53 wild-type cells (A549) by the prior administration of cytostatic compounds. Cytotoxic and cytostatic effects of ionizing radiation, cisplatin, doxorubicin and taxol, administrated alone or in combination were investigated in vitro by flow cytometry. A protective effect of doxorubicin but not cisplatin was found after administration of triple sequence with ionizing radiation and taxol. It was found that preliminary administration of doxorubicin induced growth arrest and protected A549 cells from the taxol/radiation treatment, while simultaneously killing FaDu and H1299 cells. The proposed therapeutic strategy allows protection of p53 wild-type cells and selectively increases radiosensitivity of p53-deficient cancer cells.

  • IV Delivery of Fluorescent Beads

    by Sergey V. Tokalov, Daniel Bachiller


  • Radiation-induced cell cycle arrests in Ehrlich ascites carcinoma cells in vivo

    by S. V. Tokalov, A. S. Iagunov

    Radiation-induced progression delay in G1/S, S and G2/M phases of p53 wild-type Ehrlich ascites carcinoma (EAC) cells growing in vivo was investigated by DNA flow cytometry. Different behavior patterns of EAC cells at the time after irradiation with low (2, 4, 6, 8 Gy) and high (10, 15, 20 Gy) doses were evaluated. While EAC cells showed a small progression delay in S phase and a dose-dependent block in G2/M phase after the irradiation with low doses, a clear additional block in G1/S phase was observed after irradiation with high doses. An assessment of the damage response and repair networks at the time after irradiation might have important implication for the development of cancer management and treatment.


  • Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy

    by Kornelia Szluha Lazanyi, Andrij Abramyuk, Gunter Wolf, Sergey Tokalov, Klaus Zöphel, Steffen Appold, Thomas Herrmann, Michael Baumann, Nasreddin Abolmaali


  • Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors

    by Andrij Abramyuk, Gunter Wolf, Georgy Shakirin, Ulrike Haberland, Sergey Tokalov, Arne Koch, Steffen Appold, Klaus Zöphel, Nasreddin Abolmaali

    Background: Recently published data show some controversy concerning the impact of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in predicting head and neck tumors (HNT) outcome. Assessment of tumor blood supply parameters using dynamic contrast-enhanced CT (DCE-CT) may deliver additional information concerning this important question. Purpose: To evaluate the contribution of DCE-CT implemented in pretherapeutic FDG-PET/CT protocol for prognosis prediction in patients with HNT. Material and Methods: Ten consecutive patients (median age 50 years, range 47–74 years) with histologically proven HNT underwent FDG-PET/CT with DCE-CT before treatment. FDG uptake was measured by maximum standardized uptake value (SUVmax). Relative tumor blood volume (rTBV) was determined from DCE-CT using Patlak analysis. Intratumoral heterogeneity was assessed by means of lacunarity analysis. Obtained values were compared with time-to-progression and overall survival. PET and DCE-CT images were compared on a pixel-by-pixel basis using Pearson coefficient of correlation. Results: Three patients with lower FDG uptake (SUVmax: 8±1) and five patients with higher FDG uptake (SUVmax: 15±4, P=0.004) were free of local recurrence for 24 months. Two groups of patients with significantly differing lower (group A: 0.37±0.02, n=6) and higher (group B: 0.52±0.01, n=4; P2=0.1). Conclusion: FDG-PET/CT and DCT-CT are complementary methods for surveillance assessment in patients with HNT. Implementation of DCE-CT in the pretreatment FDG-PET/CT protocol may improve tumor outcome prediction.


  • Protection of p53 Wild Type Cells From Taxol by Genistein in the Combined Treatment of Lung Cancer

    by Sergey V. Tokalov, Andrij M. Abramyuk, Nasreddin D. Abolmaali

    This study specifies the basic principles to selectively kill p53-deficient cells (H1299, FaDu) by taxol and to protect p53 wild type cells (A549) by the prior administration of structurally related flavonoids (apigenin, genistein, and quercetin). Cytotoxic and cytostatic properties of flavonoids were investigated in vitro by flow cytometry and were compared to known anticancer drugs (cisplatin, doxorubicin, etoposide). It was confirmed that doxorubicin induced growth arrest and protected A549 cells from taxol while simultaneously killing or blocking H1299 and FaDu cancer cells. It was found that doxorubicin could be successfully substituted in this way by the isoflavone genistein used at physiologically relevant concentrations. The other compounds analyzed revealed less selectivity (apigenin, cisplatin) or demonstrated higher toxicity (cisplatin, etoposide, and quercetin). We concluded that genistein-based therapy may have antagonistic effects when combined with mitotic poisons. The proposed therapeutic strategy allows protection of p53 wild type cells from taxol and selectively increases apoptosis in p53-deficient cells. This strategy exploits the naturally occurring compound that can be used without significant toxicity in rather high concentrations as present in common diets.


  • Open Access

    Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment

    by Sergey V Tokalov, Nasreddin D Abolmaali

    Mutations within the tumor suppressor TP53 gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy. The lack of the wild type TP53 gene in cancer cells could be exploited for therapeutic advantage using a sequence of two antagonistic drugs. The aim of this study was to selectively kill p53 deficient cells (FaDu and H1299) by taxol and to protect p53 wild type cells (A549) by the prior administration of nutlin-3 in comparison to certain known anticancer drugs (5-fluorouracil, camptothecin, roscovitine).


  • Open Access

    Improvement of Radiation-Mediated Immunosuppression of Human NSCLC Tumour Xenografts in a Nude Rat Model

    by Sergey V. Tokalov, Wolfgang Enghardt, Nasreddin Abolmaali

    Human tumour xenografts in a nude rat model have consistently been used as an essential part of preclinical studies for anticancer drugs activity in human. Commonly, these animals receive whole body irradiation to assure immunosuppression. But whole body dose delivery might be inhomogeneous and the resulting incomplete bone marrow depletion may modify tumour behaviour. To improve irradiation-mediated immunosuppression of human non-small cell lung cancer (NSCLC) xenografts in a nude rat model irradiation (2 + 2 Gy) from opposite sides of animals has been performed using a conventional X-ray tube. The described modification of whole body irradiation improves growth properties of human NSCLC xenografts in a nude rat model. The design of the whole body irradiation mediated immunosuppression described here for NSCLC xenografts may be useful for research applications involving other types of human tumours.